NOD mice have a generalized defect in their response to transplantation tolerance induction

Diabetes

Volumn 48, Issue 5, 1999, Pages 967-974

  Markees, Thomas G ^a   Serreze, David V ^b   Phillips, Nancy E ^a   Sorli, Christopher H ^a   Gordon, Ethel J ^a   Shultz, Leonard D ^b   Noelle, Randolph J ^c   Woda, Bruce A ^a   Greiner, Dale L ^a   Mordes, John P ^a   Rossini, Aldo A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b JACKSON LABORATORY   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 39; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENETIC DISORDER; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SKIN ALLOGRAFT; SPLEEN CELL; STREPTOZOCIN DIABETES; TRANSFUSION;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD TRANSFUSION; CD40 LIGAND; DIABETES MELLITUS, TYPE 1; FEMALE; GRAFT REJECTION; IMMUNE TOLERANCE; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; SKIN TRANSPLANTATION; THYMECTOMY; TISSUE DONORS; TRANSPLANTATION CONDITIONING;

EID: 0032910231     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.5.967     Document Type: Article

References (41)

1. Boitard C, Timsit J, Larger E, Dubois D: Immune mechanisms leading to type 1 insulin-dependent diabetes mellitus. Horm Res 48 (Suppl. 4):58-63, 1997
2. Verge CF, Eisenbarth GS: Natural history of autoimmunity in type I diabetes mellitus. In Diabetes Mellitus: A Fundamental and Clinical Text, LeRoith D, Taylor SI, Olefsky JM, Eds. Philadelphia, Lippincott-Raven, 1996, p. 287-297
3. Steffes MW, Sutherland DE, Goetz FC, Rich SS, Mauer SM: Studies of kidney and muscle biopsy specimens from identical twins discordant for type I diabetes mellitus. N Engl J Med 312:1282-1287, 1985
4. Secchi A, Di Carlo V, Pozza G: Pancreas and islet transplantation: current progresses, problems and perspectives. Horm Metab Res 29:1-8, 1997
5. Leiter E: Genetics and immunogenetics of NOD mice and related strains. In NOD Mice and Related Strains: Research Applications in Diabetes, AIDS, Cancel; and Other Diseases. Leiter E, Atkinson M, Eds. Austin, TX, RG Landes, 1998, p. 37-69
6. Serreze DV, Gaedeke JW, Leiter EH: Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. Proc Natl Acad Sci USA 90:9625-9629, 1993
7. Kataoka S, Satoh J, Fujiya H, Toyota T, Suzuki R, Itoh K, Kumagai K: Immunologic aspects of the nonobese diabetic (NOD) mouse. Diabetes 32:247-253, 1983
8. Serreze DV, Leiter EH: Defective activation of T suppressor cell function in nonobese diabetic mice: potential relation to cytokine deficiencies. J Immunol 140:3801-3807, 1988
9. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, Leiter EH: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 154:180-191, 1995
10. Baxter AG, Cooke A: Complement lytic activity has no role in the pathogenesis of autoimmune diabetes in NOD mice. Diabetes 42:1574-1578, 1993
11. Bowman MA, Leiter EH, Atkinson MA: Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol Today 15:115-120, 1994
12. Sandberg JO, Eizirik DL, Sandler S: IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin Exp Immunol 108:314-317, 1997
13. Chen HM, Jovanovic-Peterson L, Desai TA, Peterson CM: Lessons learned from the non-obese diabetic mouse. 2. Amelioration of pancreatic autoimmune isograft rejection during pregnancy. Am J Perinatol 13:249-254, 1996
14. Faust A, Rothe H, Schade U, Lampeter E, Kolb H: Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10. Transplantation 62:648-652, 1996
15. Lakey JRT, Warnock GL, Singh B, Rajotte RV: Adjuvant immunotherapy with bacillus Calmette-Guerin prevents recurrence of diabetes in islet grafts transplanted into NOD mice. Transplant Proc 26:736-736, 1994
16. Nomikos IN, Prowse SJ, Carotenuto P, Lafferty KJ: Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice. Diabetes 35:1302-1304, 1986
17. Atkinson MA: NOD mice as a model for therapeutic interventions in human insulin dependent diabetes mellitus. In NOD Mice and Related Strains: Research Applications in Diabetes, AIDS, Cancer and Other Diseases. Leiter EH, Atkinson MA, Eds. Austin, TX, RG Landes, 1998, p. 145-172
18. Maki T, Ichikawa T, Blanco R, Porter J: Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Nail Acad Sci USA 89:3434-3438, 1992
19. Parker DC, Greiner DL, Phillips NE, Appel MC, Steele AW, Durie FH, Noelle RJ, Mordes JP, Rossini AA: Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 92:9560-9564, 1995
20. Rossini AA, Mordes JP, Markees TG, Phillips NE, Gordon EJ, Greiner DL: Induction of islet transplantation tolerance using donor specific transfusion and anti-CD154 monoclonal antibody. Transplant Proc 31:629-632, 1999
21. + T cells, interferon-gamma, and CTLA4. J Clin Invest 101:2446-2455, 1998
22. Markees TG, Phillips NE, Noelle RJ, Shultz LD, Mordes JP, Greiner DL, Rossini AA: Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. Transplantation 64:329-335, 1997
23. Balasa B, Krahl T, Patstone G, Lee J, Tisch R, McDevitt HO, Sarvetnick N: CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 159:4620-4627, 1997
24. Van den Eertwegh AJM, Noelle RJ, Roy M, Shepherd DM, Aruffo A, Ledbetter JA, Boersma WJA, Claassen E: In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J Exp Med 178:1555-1565, 1993
25. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ: In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med 178:1567-1575, 1993
26. Rossini AA, Greiner DL, Mordes JP: Induction of immunological tolerance for transplantation. Physiol Rev 79:99-141, 1999
27. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. JAm Statist Assn 53:457-481, 1958
28. Matthews DE, Farewell VT: The log-rank or Mantel-Haenszel test for the comparison of survival curves. In Using and Understanding Medical Statistics. 2nd ed. Matthews DE, Farewell VT, Eds. Basel, Karger, 1988, p. 79-87
29. Rossini AA, Parker DC, Phillips NE, Durie FH, Noelle RJ, Mordes JP, Greiner DL: Induction of immunological tolerance to islet grafts. Cell Transplantation 5:49-52, 1996
30. Gonzalez A, Katz JD, Mattei MG, Kikutani H, Benoist C, Mathis D: Genetic control of diabetes progression. Immunity 7:873-883, 1997
31. Schöne G: Die Heteroplastische und Homöoplastische Transplantation. Berlin, Springer-Verlag, 1912, p. 73-74
32. Markees TG, Phillips NE, Gordon EJ, Noelle RJ, Mordes JP, Greiner DL, Rossini AA: Improved skin allograft tolerance induced by treatment with donor splenocytes and an extended course of anti-CD154 monoclonal antibody. Transplant Proc 30:2444-2446, 1998
33. Markees TG, Noelle R, Mordes JP, Greiner DL, Rossini AA: Prolongation of skin allograft survival with allogeneic donor splenocytes (SPC) and monoclonal antibody (mAb) to CD40 ligand (CD40L) (Abstract). Diabetes 45 (Suppl. 2):24A, 1996
34. Markees TG, Phillips NE, Gordon EJ, Noelle RJ, Mordes JP, Greiner DL, Rossini AA: Prolonged skin allograft survival in mice treated with Flt3-ligand-induced dendritic cells and anti-CD154 monoclonal antibody. Transplant Proc 31:884-685, 1999
35. Ridgway WM, Ito H, Fassò M, Yu C, Fathman CG: Analysis of the role of variation of major histocompatibity complex class II expression on nonobese diabetic (NOD) peripheral T cell response. J Exp Med 188:2267-2275, 1998
36. Serreze DV, Gaskins HR, Leiter EH: Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol 150:2534-2543, 1993
37. Serreze DV, Leiter EH: Insulin dependent diabetes mellitus (IDDM) in NOD mice and BB rats: origins in hematopoietic stem cell defects and implications for therapy. In Lessons from Animal Diabetes V. Shafrir E, Ed. London, Smith Gordon, 1994, p. 59-73
38. Van Kooten C, Banchereau J: CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol 61:1-77, 1996
39. + T-cell responses. Immunol Today 17:410-414, 1996
40. Stout RD, Suttles J: The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today 17:487-492, 1996
41. Eisenbarth GS, Ziegler AG, Colman PA: Pathogenesis of insulin-dependent (type I) diabetes mellitus. In Joslin's Diabetes Mellitus. 13th ed. Kahn CR, Weir GC, Eds. Malvern, PA, Lea & Febiger, 1994, p. 216-239